Pharmafile Logo
Pharmafocus logo
Advanced Search

Eisai

Showing 15 posts of 114 posts found.

Zonegran study could pave way for paediatric licence

September 2, 2011
Research and Development, Sales and Marketing Eisai, Zonegran, epilepsy, research and development news

Eisai’s epilepsy drug Zonegran has been found more effective than placebo in children with the neurological condition who have seizures. …

News
FDA building

FDA refuses to file Eisai’s epilepsy drug

August 1, 2011
Sales and Marketing Eisai, FDA, epilepsy

The FDA has refused to file Eisai’s epilepsy drug perampanel, saying it needs more information for the treatment. The FDA …

News

NICE says no to breast cancer treatment Halaven

July 20, 2011
Sales and Marketing Eisai, Halaven, NICE

Eisai’s Halaven has been rejected by NICE in draft guidance for locally advanced or metastatic breast cancer. Halaven (eribulin) is …

News

Eisai extends neuroscience partnership with UCL

May 25, 2011
Research and Development Eisai, UCL, academic alliance, academic research, neurodegenerative diseases

Eisai and University College London are to extend their partnership in neuroscience research. The Japanese company’s Neuroscience Product Creation Unit …

News

Eisai launches cancer drug Halaven in UK

April 20, 2011
Sales and Marketing Eisai, Halaven, breast cancer

Eisai’s sea sponge derived breast cancer drug Halaven has been launched in the UK following approval from European regulators a …

News

Eisai sets up in Brazil

April 8, 2011
Sales and Marketing Brazil, Eisai

Japanese pharma company Eisai has set up its first operations in Latin America, establishing a sales subsidiary in Brazil. Based …

News

Eisai marine sponge derived cancer drug approved in Europe

March 23, 2011
Sales and Marketing Cancer, Eisai, Halaven, Halichondria okadai, breast cancer, eribulin mesylate

Eisai’s injectible breast cancer drug Halaven has been approved by European regulators. The highly novel drug is made from a …

News
Japanese rescue workers

Japan’s pharma industry pledges to maintain medicines supply

March 17, 2011
Sales and Marketing Astellas, Boehringer Ingelheim, Daiichi Sankyo, Eisai, Japan, earthquake

Pharmaceutical firms in Japan have escaped the very worst of the devastation caused by the earthquake and tsunami, and have …

News

Eisai confirms 20% cut in US workforce

March 8, 2011
Manufacturing and Production, Research and Development, Sales and Marketing Aricept, Eisai, Halaven, US, donepezil, eribulin, pharma job cuts

Eisai’s planned job cuts will fall heaviest on its US operations, where 20% of the workforce will be let go …

News

Eisai prepares ground for Halaven’s European launch

March 7, 2011
Sales and Marketing Cancer, EMBRACE, Eisai, Halaven, advanced breast cancer, breast cancer, eribulin

Eisai has published further details of a phase III trial of its first-in-class chemotherapy drug Halaven ahead of its hoped-for …

News

Eisai to cut 900 jobs ahead of Aricept patent loss

March 7, 2011
Sales and Marketing Aricept, Eisai, donepezil, generics, job cuts

Eisai is to cut around 900 jobs in Europe, the US and Japan over the next five years as it …

News

Eisai sepsis drug fails in phase III

January 26, 2011
Research and Development, Sales and Marketing Eisai, eritoran, perampanel, sepsis

A new treatment for severe sepsis could be abandoned entirely after phase III results fell short. Eisai’s eritoran did not …

News

FDA approves Eisai breast cancer drug Halaven

November 16, 2010
Sales and Marketing Cancer, Eisai, FDA, Halaven, Xeloda, breast cancer, eribulin mesylate, metastatic breast cancer

The FDA has approved Eisai’s advanced breast cancer drug Halaven for use in heavily pre-treated breast cancer patients. Halaven (eribulin …

News

Arena’s obesity treatment lorcaserin rejected by FDA

October 25, 2010
Sales and Marketing Arena Pharma, Eisai, FDA, FDA complete response letter, lorcaserin, obesity

A new weight loss drug has been rejected by the FDA because of numerous concerns about side-effects and limited efficacy. …

News

Encouraging data for Eisai epilepsy drug

August 24, 2010
Sales and Marketing Eisai, epilepsy, perampanel, phase III, seizures, study 306

A new phase III study for Eisai’s perampanel (E2007) suggests the first-in-class treatment is effective as an adjunctive treatment of …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025